Literature DB >> 1722089

Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies.

T G Besselaar1, N K Blackburn.   

Abstract

A panel of 17 monoclonal antibodies (MAbs) to the G1 and G2 envelope glycoproteins of Rift Valley fever (RVF) virus were used to analyze the topography and functional properties of the viral antigenic sites. Four heterogeneous antigenic regions which may be interlinked were identified on the G1 protein and four distinct domains on the G2 protein by competitive binding assays. Comparison of the biological activities and epitope specificities of the MAbs against G1 showed that the antigenic domains I, II, and IV were involved in virus neutralization and haemagglutination at different potencies. For both the G1 and G2 proteins, determinants mapping to domain G1 Ia and G2 Ia were associated with very strong neutralization independent of complement (C'), suggesting that they represent biologically important areas. Domain G2 II was involved in haemagglutination and weak C' dependent neutralization while the other two G2 regions had no haemagglutination function and neutralized to a low level only in the presence of C'. Epitopes Ia and IIb on G1 and Ia and IIa on G2 were also associated with protection of mice against virulent RVFV infection, indicating that both envelope glycoproteins play an important role in RVF viral infection and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722089     DOI: 10.1007/bf01316748

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  33 in total

1.  Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins.

Authors:  C S Schmaljohn; M D Parker; W H Ennis; J M Dalrymple; M S Collett; J A Suzich; A L Schmaljohn
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

2.  Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus.

Authors:  K Keegan; M S Collett
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

3.  Envelopments of Sindbis virus: synthesis and organization of proteins in cells infected with wild type and maturation-defective mutants.

Authors:  J F Smith; D T Brown
Journal:  J Virol       Date:  1977-06       Impact factor: 5.103

4.  Comparison of techniques for demonstrating antibodies to Rift Valley fever virus.

Authors:  R Swanepoel; J K Struthers; M J Erasmus; S P Shepherd; G M McGillivray; B J Erasmus; B J Barnard
Journal:  J Hyg (Lond)       Date:  1986-10

5.  Enhanced neutralization of La Crosse virus by the binding of specific pairs of monoclonal antibodies to the G1 glycoprotein.

Authors:  L Kingsford
Journal:  Virology       Date:  1984-07-30       Impact factor: 3.616

6.  Biological activities of monoclonal antibodies reactive with antigenic sites mapped on the G1 glycoprotein of La Crosse virus.

Authors:  L Kingsford; L D Ishizawa; D W Hill
Journal:  Virology       Date:  1983-09       Impact factor: 3.616

7.  Topological mapping antigenic sites on the influenza A/PR/8/34 virus hemagglutinin using monoclonal antibodies.

Authors:  M D Lubeck; W Gerhard
Journal:  Virology       Date:  1981-08       Impact factor: 3.616

8.  Biochemical characterization of Rift Valley fever virus.

Authors:  R M Rice; B J Erlick; R R Rosato; G A Eddy; S B Mohanty
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

9.  An investigation of flavivirus infections of cattle in Zimbabwe Rhodesia with particular reference to Wesselsbron virus.

Authors:  N K Blackburn; R Swanepoel
Journal:  J Hyg (Lond)       Date:  1980-08

10.  Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities.

Authors:  W A Boere; T Harmsen; J Vinjé; B J Benaissa-Trouw; C A Kraaijeveld; H Snippe
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

View more
  24 in total

1.  The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins.

Authors:  T G Besselaar; N K Blackburn
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Characterization of the Candiru antigenic complex (Bunyaviridae: Phlebovirus), a highly diverse and reassorting group of viruses affecting humans in tropical America.

Authors:  Gustavo Palacios; Robert Tesh; Amelia Travassos da Rosa; Nazir Savji; Wilson Sze; Komal Jain; Robert Serge; Hilda Guzman; Carolina Guevara; Marcio R T Nunes; Joaquim P Nunes-Neto; Tadeusz Kochel; Stephen Hutchison; Pedro F C Vasconcelos; W Ian Lipkin
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 3.  Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.

Authors:  Kaori Terasaki; Breanna R Tercero; Shinji Makino
Journal:  Virus Res       Date:  2015-05-27       Impact factor: 3.303

4.  Granada virus: a natural phlebovirus reassortant of the sandfly fever Naples serocomplex with low seroprevalence in humans.

Authors:  Ximena Collao; Gustavo Palacios; Fernando de Ory; Sara Sanbonmatsu; Mercedes Pérez-Ruiz; José María Navarro; Ricardo Molina; Stephen K Hutchison; W Ian Lipkin; Antonio Tenorio; María Paz Sánchez-Seco
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

5.  Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization.

Authors:  Raquel Martín-Folgar; Gema Lorenzo; Hani Boshra; Javier Iglesias; Francisco Mateos; Belén Borrego; Alejandro Brun
Journal:  MAbs       Date:  2010-05-02       Impact factor: 5.857

6.  Performance of various commercial assays for the detection of Toscana virus antibodies.

Authors:  Koray Ergünay; Nadine Litzba; Modou Moustapha Lo; Sibel Aydoğan; Mehmet B Saygan; Dürdal Us; Manfred Weidmann; Matthias Niedrig
Journal:  Vector Borne Zoonotic Dis       Date:  2011-03-11       Impact factor: 2.133

7.  Rapid accumulation of virulent rift valley Fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the m RNA.

Authors:  John C Morrill; Tetsuro Ikegami; Naoko Yoshikawa-Iwata; Nandadeva Lokugamage; Sungyong Won; Kaori Terasaki; Aya Zamoto-Niikura; C J Peters; Shinji Makino
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

8.  Humoral response in Toscana virus acute neurologic disease investigated by viral-protein-specific immunoassays.

Authors:  F Magurano; L Nicoletti
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

9.  Development and Characterization of Monoclonal Antibodies Directed Against the Nucleoprotein of Heartland Virus.

Authors:  Amanda E Calvert; Aaron C Brault
Journal:  Am J Trop Med Hyg       Date:  2015-10-26       Impact factor: 2.345

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.